CLAIMS

1. An infused edible in the form of a fixed unit dosage form for use in the treatment of at least one of sexual arousal disorder or orgasmic disorder in a human, the infused edible including:

a sexual pleasure enhancing component comprising a therapeutically effective amount of one or more cannabinoid compounds, including at least one of 5 mg to 500 mg of tetrahydrocannabinol (THC) and 5 mg to 500 mg of cannabidiol (CBD), and a sexual response enhancing component comprising a therapeutically effective amount of one or more components, which are not cannabinoids, that raise blood level of nitric oxide (NO) and increase blood flow to the genital region of the human.

2. The infused edible of claim 1, wherein the infused edible is selected from oral drops, lozenges, lollipops, food preparations, brownies, cookies, chocolates, chews, gum drops, soft candies, hard candies, and liquid shots.

3. The infused edible of claim 1 or 2, wherein the sexual response enhancing component is selected from sildenafil, tadalafil, vardenafil, L-arginine, L-citrulline, yohimbe root, ginseng, ginkgo biloba, horny goat weed, goosefoot, Chenopodium ambrosioides, Chlorophytum borivilianum, Desmodium gangeticum, garlic combined with vitamin C, and damiana.

4. The infused edible of any one of claims 1-3, wherein the human is a woman and the infused edible is for use in the treatment of at least one of sexual arousal disorder or orgasmic disorder in the woman and is effective in increasing at least one of threshold sexual desire, sexual sensitivity, sexual pleasure, ability to orgasm, and strength of orgasm in the woman.

5. The infused edible of any one of claims 1-3, wherein the human is a man and the infused edible is for use in the treatment of at least one of sexual arousal disorder or orgasmic disorder in the man and is effective in increasing at least one of threshold sexual desire, sexual sensitivity, sexual pleasure, ability to orgasm, and strength of orgasm in the man.

6. The infused edible of claim 5, wherein the infused edible is further effective in increasing ability of a man to achieve and/or maintain an erection.

7. The infused edible of any one of claims 1-6, wherein the one or more cannabinoid compounds comprise at least one of cannabinol (CBN), tetrahydrocannabivarin (THCV), cannabigerol (CBG), dronabinol, nabilone, derivative of THC, and derivative of CBD.

8. The infused edible of any one of claims 1-7, wherein the infused edible comprises THC and CBD in a ratio of THC/CBD of at least 2:1, or 3:1 to 20:1, or 4:1 to 15.

9. The infused edible of any one of claims 1-7, wherein the infused edible comprises CBD and THC in a ratio of CBD/THC of at least 2:1, or 3:1 to 20:1, or 4:1 to 15.

10. The infused edible of any one of claims 1-7, wherein the infused edible comprises THC and CBD in a ratio of THC/CBD of 0.5:1 to 2:1.

11. A pharmaceutical composition for use in the treatment of orgasmic disorder in a human, comprising:

a sexual pleasure enhancing component including at least one of 5 mg to 500 mg of tetrahydrocannabinol (THC) in a fixed unit dosage and 5 mg to 500 mg of cannabidiol (CBD) in a fixed unit dosage; and a therapeutically effective amount of a sexual response enhancing component comprising one or more components, which are not cannabinoids, that raise blood level of nitric oxide (NO) and increase blood flow to the genital region of the human, wherein:

when the human is a woman, the composition is for use in treating an orgasmic disorder in the woman and is effective in increasing at least one of sexual pleasure, ability to orgasm, and strength of orgasm in the woman,

when the human is a man, the composition is for use in treating an orgasmic disorder in the man and is effective in increasing at least one of sexual pleasure, ability to orgasm, and strength of orgasm in the man.

12. The pharmaceutical composition of claim 11, wherein the sexual response enhancing component is a PDE5 inhibitor selected from sildenafil, tadalafil, and vardenafil.

13. The pharmaceutical composition of claim 11, wherein the sexual response enhancing component is selected from L-arginine, L-citrulline, yohimbe root, ginseng, ginkgo biloba, horny goat weed, goosefoot, Chenopodium ambrosioides, Chlorophytum borivilianum, Desmodium gangeticum, garlic combined with vitamin C, and damiana.

14. The pharmaceutical composition of any one of claims 11-13, wherein the pharmaceutical composition is a tablet or capsule.

15. The pharmaceutical composition of any one of claims 11-13, wherein the pharmaceutical composition comprises a vaginal suppository, anal suppository, genital spray, patch, or liquid formulation.

16. The pharmaceutical composition of any one of claims 11-13, wherein the pharmaceutical composition is formulated for vaporization and inhalation without smoking using a heat vaporizer or a nebulizer.

17. The pharmaceutical composition of any one of claims 11-16, wherein the human is a woman and the pharmaceutical composition is effective in increasing at least one of threshold sexual desire, sexual sensitivity, sexual pleasure, ability to orgasm, and strength of orgasm.

18. The pharmaceutical composition of any one of claims 11-16, wherein the human is a man and the pharmaceutical composition is effective in increasing at least one of sexual pleasure, ability to orgasm, and strength of orgasm.

19. The pharmaceutical composition of any one of claims 11-18, wherein the pharmaceutical composition comprises THC and CBD in a ratio of THC/CBD of at least 2:1, or 3:1 to 20:1, or 4:1 to 15.

20. The pharmaceutical composition of any one of claims 11-18, wherein the pharmaceutical composition comprises CBD and THC in a ratio of CBD/THC of at least 2:1, or 3:1 to 20:1, or 4:1 to 15.

21. The pharmaceutical composition of any one of claims 11-18, wherein the pharmaceutical composition comprises THC and CBD in a ratio of THC/CBD of 0.5:1 to 2:1.

22. The pharmaceutical composition of any one of claims 11-21, wherein the one or more cannabinoid compounds comprise at least one of cannabinol (CBN), tetrahydrocannabivarin (THCV), cannabigerol (CBG), dronabinol, nabilone, derivative of THC, and derivative of CBD.

23. A kit for use in the treatment of at least one of sexual arousal disorder and orgasmic disorder in a human, comprising:

a cannabinoid dosage form formulated for vaporization and inhalation without smoking using a heat vaporizer or nebulizer and that provides a therapeutically effective dose of at least one of tetrahydrocannabinol (THC) and cannabidiol (CBD); and

a tablet, capsule, infused edible, or topical dosage form that contains a therapeutically effective amount of a sexual response enhancing component, which is not a cannabinoid, that raises blood level of nitric oxide (NO) and increase blood flow to the genital region of the human.

24. The kit of claim 23, wherein the sexual response component is selected from sildenafil, tadalafil, vardenafil, L-arginine, L-citrulline, yohimbe root, ginseng, ginkgo biloba, horny goat weed, goosefoot, Chenopodium ambrosioides, Chlorophytum borivilianum, Desmodium gangeticum, garlic combined with vitamin C, and damiana.

25. The kit of claim 23 or 24, wherein the human is a woman and the kit is for use in treating at least one of sexual arousal disorder and orgasmic disorder in the woman and is effective in increasing at least one of threshold sexual desire, sexual sensitivity, sexual pleasure, ability to orgasm, and strength of orgasm in the woman.

26. The kit of claim 23 or 24, wherein the human is a man and the kit is for use in treating at least one of sexual arousal disorder and orgasmic disorder in the man and is effective in increasing at least one of threshold sexual desire, sexual sensitivity, sexual pleasure, ability to orgasm, and strength of orgasm in the man.

27. The kit of claim 26, wherein the kit is further effective in increasing ability of a man to achieve and/or maintain an erection.

28. The kit of any one of claims 23-27, wherein the cannabinoid dosage form is a fixed unit dosage form and provides at least one of THC and CBD in a range of 5 mg to 500 mg, or 7.5 mg to 450 mg, or 10 mg to 400 mg, or 15 mg to 350 mg, or 20 mg to 300, or 25 mg to 250 mg, or 35 mg to 200 mg.

29. The kit of any one of claims 23-28, wherein the cannabinoid dosage form comprises THC and CBD in a ratio of THC/CBD of at least 2:1, or 3:1 to 20:1, or 4:1 to 15.

30. The kit of any one of claims 23-28, wherein the cannabinoid dosage form comprises CBD and THC in a ratio of CBD/THC of at least 2:1, or 3:1 to 20:1, or 4:1 to 15.

31. The kit of any one of claims 23-28, wherein the cannabinoid dosage form comprises THC and CBD in a ratio of THC/CBD of 0.5:1 to 2:1.

32. The kit of any one of claims 23-31, wherein the one or more cannabinoid compounds comprise at least one of cannabinol (CBN), tetrahydrocannabivarin (THCV), cannabigerol (CBG), dronabinol, nabilone, derivative of THC, and derivative of CBD.

33. A kit for use in the treatment of at least one of sexual arousal disorder and orgasmic disorder in a human, comprising:

a topical dosage form selected from massage oil, sexual lubricant, and patch and that provides a therapeutically effective dose of at least one of tetrahydrocannabinol (THC) and cannabidiol (CBD); and a tablet, capsule, infused edible, or topical dosage form that contains a therapeutically effective amount of a sexual response enhancing component, which is not a cannabinoid, that raises blood level of nitric oxide (NO) and increase blood flow to the genital region.

34. A kit for use in the treatment of at least one of sexual arousal disorder and orgasmic disorder in a human, comprising:

a suppository selected from vaginal suppository and anal suppository and that provides a therapeutically effective dose of at least one of tetrahydrocannabinol (THC) and cannabidiol (CBD); and a tablet, capsule, infused edible, or topical dosage form that contains a therapeutically effective amount of a sexual response enhancing component, which is not a cannabinoid, that raises blood level of nitric oxide (NO) and increase blood flow to the genital region.

35. The kit of claim 34, wherein the sexual response component is a PDE5 inhibitor selected from sildenafil, tadalafil, and vardenafil.